BriaCell Therapeutics Corp. (BCTX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en West Vancouver, BC, Canada. El CEO actual es William V. Williams.
BCTX tiene fecha de IPO 2012-03-14, 16 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $8.7M.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
